HealthCare Global Enterprises Ltd

NSE HCG BSE 539787 hcgoncology.com Investor relations

Q1 FY27, unaudited

Revenue: ₹695.10 Cr
Profit after tax: ₹16.46 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ crore	Q1 FY27	vs a year ago	FY26
Revenue from operations	695.10	+13.36%	2,545.41
Other income	12.13	+77.60%	24.99
Total income	707.23	+14.07%	2,570.40
Employee benefit expense	104.52	+6.90%	378.60
Finance costs	39.87	−12.32%	176.57
Depreciation & amortisation	70.42	+21.60%	244.17
Total expenses	683.13	+12.22%	2,500.36
Profit before tax	24.10	+114.41%	25.46
Tax expense	8.57	+44.28%	4.14
Profit after tax	16.46	+175.25%	22.78
Total comprehensive income	16.95	+172.07%	27.33

Earnings per share
Earnings per share, basic	₹0.92	₹0.97
Earnings per share, diluted	₹0.92	₹0.96

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q1 FY27

HCG reported Q1 FY27 revenue of INR6,951 million, up approximately 13% year-on-year, driven by an 11% increase in patient volumes and 2% ARPP growth. Adjusted EBITDA rose 20% year-on-year to INR1,339 million with margins improving to 19.4% from 18.2% in Q1 FY26. Management discussed the North Bangalore hospital ramp-up, bed capacity expansion plans, the completed Fertility business divestment, and use of rights issue proceeds for debt repayment and the Vizag stake increase.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 49 published by the exchange

25 Aug 2026
Filing
Newspaper Publication
10 Aug 2026
Transcript
Earnings Call Transcript
08 Aug 2026
Filing
Newspaper Publication
07 Aug 2026
Concall
Analyst / Investor Meet - Intimation
07 Aug 2026
Concall
Analyst / Investor Meet - Outcome
06 Aug 2026
Filing
Press Release / Media Release
06 Aug 2026
Presentation
Investor Presentation
06 Aug 2026
Filing
Monitoring Agency Report
06 Aug 2026
Filing
Statement Of Variation Or Deviation Of The Proceeds Of Rights Issue For The Quarter Ended June 30, 2026.
06 Aug 2026
Filing
Change in Management
06 Aug 2026
Filing
Acquisition
06 Aug 2026
Results
Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026.

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.